- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07587112
Explore Neural Mechanism of OCD by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation
The purpose of this study is to investigate the differences in therapeutic efficacy of different deep TMS treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.
Inclusion Criteria:
Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.
- Study Design: Double-blind, randomized assignment.
Number of Participants:
Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants
Study Procedures:
- Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.
Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms (Carmi et al., 2018).
Complete baseline symptom severity assessments and brain positron emission tomography/magnetic resonance imaging (PET/MRI). Participants with structural brain abnormalities will be excluded.
Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.
Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.
- Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).
Approximately 3-5 minutes before each TMS session, trained personnel with ERP experience will assist participants in symptom provocation and record the participant's subjective level of distress.
The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.
After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.
Symptom severity interviews will be conducted every two weeks.
- Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET/MRI.
At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.
Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.
Statistical Analysis
- Expected Outcomes:
The H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.
- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in MADRS, Y-BOCS, HAM-A, HDRS, and CGI-S scores.
The percentage of responders (% responders) will be calculated and compared among groups.
Repeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.
Pearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET/MRI neuroimaging measures.
- PET/MRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.
Changes in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Cheng-Ta Li
- Numero di telefono: 886-2-55704055
- Email: ctli0420@gmail.com
Backup dei contatti dello studio
- Nome: Chia-Min Huang
- Email: psygrace1@gmail.com
Luoghi di studio
-
-
-
Taipei, Taiwan
- Reclutamento
- Taipei Veterans General Hospital
-
Contatto:
- Cheng-Ta Li
- Numero di telefono: 886-2-55704055
- Email: ctli0420@gmail.com
-
Contatto:
- Chia-Min Huang
- Email: psygrace1@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Adults aged 18-65 years.
- Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.
- Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.
Exclusion Criteria:
- Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.
- High suicide risk within the past year.
- Presence of significant medical or surgical conditions in an active phase.
- History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).
- Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).
- Pregnant women.
- Inability to tolerate PET/MRI examination due to claustrophobia or severe anxiety in confined spaces.
- Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.
- Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).
- Known allergy to 18F-FDG.
- History of adverse reaction to TMS or allergy to the positioning cap.
- Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).
- Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Active H7 coil stimulation
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
|
Comparatore fittizio: Sham stimulation group
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
|
Sperimentale: Active H1 coil group
|
Sham dTMS Participants will receive sham deep TMS using a sham coil. H7 dTMS Participants will receive active deep TMS using the H7 coil. H1 dTMS Participants will receive active deep TMS using the H1 coil. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
the percentage changes in Y-BOCS scores after treatments
Lasso di tempo: the 6-week and 8-week
|
Two time-spans are assessed: (a) from baseline (Week 0, W0) to posttreatment (Week 6, W6), and (b) from baseline (W0) to the 2-week follow-up (Week 8, W8). The percentage changes in Y-BOCS scores will be calculated as follows:
|
the 6-week and 8-week
|
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2024-06-004C
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Sham deep TMS (control stimulation) & H7 deep TMS (active treatment) & H1 deep TMS (active treatment)
-
Ben-Gurion University of the NegevBrainswayReclutamentoDisturbo ossessivo compulsivoIsraele
-
Rotman Research Institute at BaycrestReclutamentoCompromissione cognitiva lieve (MCI) | Declino cognitivo soggettivo (SCD)Canada
-
Rotman Research Institute at BaycrestReclutamentoDisturbo depressivo maggiore (MDD)Canada
-
St. Joseph's Healthcare HamiltonPeter Boris Centre for Addictions Research (PBCAR)CompletatoDisturbo depressivo maggioreCanada
-
BeerYaakov Mental Health CenterWeizmann Institute of ScienceSconosciuto
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR); BrainswayCompletatoDisturbo depressivo maggioreCanada
-
IRCCS San Raffaele RomaCompletatoMorbo di Parkinson | Paralisi sopranucleare progressivaItalia
-
St. Joseph's Healthcare HamiltonReclutamentoDisturbo neurocognitivo lieveCanada
-
Rotman Research Institute at BaycrestCentre for Addiction and Mental Health; BrainswayReclutamentoMalattia di Alzheimer | Compromissione cognitiva lieve | Disturbo depressivo maggioreCanada
-
Centre hospitalier de l'Université de Montréal...CompletatoDisturbo da uso di stimolantiCanada